Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 VLP influenza vaccine
- Development stage
- Phase 2
- Lead developer
- Medicago
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The H5 VLP influenza vaccine is a plant-derived virus-like particle (VLP) vaccine candidate developed by Medicago for the prevention of H5N1 pandemic influenza. Produced using Medicago's proprietary Proficia platform, which utilizes *Nicotiana benthamiana* plants as bioreactors, the vaccine consists of recombinant hemagglutinin (HA) proteins that self-assemble into non-infectious particles mimicking the structure of the influenza virus. These VLPs are designed to induce a robust immune response against the H5 antigen without the need for live virus during manufacturing. The vaccine has been evaluated in Phase 1 and Phase 2 clinical trials, often in combination with the adjuvant Alhydrogel (aluminum hydroxide) to enhance immunogenicity. Although the program showed promise in pandemic preparedness, its primary developer, Medicago, ceased operations in early 2023.
- Other names
- Plant-based H5 VLPH5N1 VLP vaccineH-5N1 VLP vaccineH 5N1 VLP vaccineMedicago H5 VLP vaccineH5 VLP influenza vaccineH-5 VLP influenza vaccineH 5 VLP influenza vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)M1 (Muscarinic acetylcholine receptor M1)Neuraminidase
Beyond the preview
Go deeper on H5 VLP influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 VLP influenza vaccine.